Reviewer’s report

Title: A Phase II Study of LFP Therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-Dose Consecutive (Cisplatin) CDDP) in Advanced Biliary tract Carcinoma

Version: 10 Date: 1 February 2006

Reviewer: Nicolas Tsavaris

Reviewer’s report:

General
Introduction:
Biliary tract cancers are unknowns in North America. Better expression is rare. “As a result, an effective chemotherapy……..respectively (3,4,10)” This sentence needs to be re-written, because many efforts had been done. On the other hand the poor results of all these trials and some times the mature confuted results I think that spotlight the results of this trial with two old cytostatics which is administered in this trial with a modern way.

Patients and Method
There is no description of patients characteristics. In Table 1 there are no data about the extension of the disease and the kind of metastases. These data are partial included in results but this makes a confusion to the reader.

Page 13.
“Our main objective…..response rate”. I think that this sentence must be omitted, as well as this must be putted in the Introduction, especially I think that this modality is not so friendly for the patient.

Response
Response evaluation needs more details and not a reference (20). This is necessary because all oncologists know how difficult is to evaluate the response rate in tumors of this area (pancreatic and chollangiocarcinomas.

Table 1.

Results
Confirmation of response needs a duration at least two months in all evaluations about.

Page 5
The Cox…..track malignancy. It is absturse for understanding, I think must be omitted.

Page 12
These doses…gastric cancer. Needs references and not this expression.

Toxicity
Toxicity – Ascites, is a misunderstanding point.

Response
Results in response is another complicated point.

------------------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

------------------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

------------------------------------------------------------------------------------------
Discretionary Revisions (which the author can choose to ignore)

**What next?:** Reject because too small an advance to publish